MYLK and pulmonary arterial hypertension: Treatment of BMPR2 silenced and VEGF treated HPAECs with the MLCK specific inhibitor (ML-7) resulted in decreased proliferation and migration further promoting the novel identification of nmMLCK playing an important role in PAH pathogenesis.